Amgen announced that it will collaborate with the National Cancer Institute and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles.
In the U.S., lung cancer is the leading cause of cancer death and the second most common cancer.1 Approximately 25-30 percent of non-small cell lung cancers, the most common form of lung cancer, are squamous cell carcinomas. However, there are limited treatment options available for squamous cell carcinomas and development of treatments has been further complicated by the number of potential genetic mutations associated with this form of cancer. Research has demonstrated that squamous cell lung cancer has more than double the genetic mutations compared to other forms of cancer.
Lung-MAP is a biomarker-driven, multi-drug, multi-arm Phase 2/3 registration clinical trial for patients with squamous cell lung cancer. The trial will evaluate five investigational compounds intended to treat squamous cell lung cancer and use genomic sequencing to assign enrolled patients to the treatment arms most likely to provide benefit. Patients will then be randomized into one of five sub-studies where they will receive either standard of care (docetaxel or erlotinib) or biomarker-driven targeted therapy with an investigational agent. Each of these sub-studies will be independently powered for overall survival (OS) with an interim analysis for progression-free survival (PFS) to determine whether to proceed from Phase 2 into Phase 3.
Approximately 500 to 1,000 patients will be screened each year for more than 200 cancer-related genes, and the screenings will inform trial arm selection. Five investigational drugs have been selected for inclusion in the initial trial, including Amgen's rilotumumab, an investigational fully human monoclonal antibody designed to inhibit cancer cell growth and migration.
"Amgen has been at the forefront of biomarker research in an effort to help the medical community understand the different mechanisms of cancer progression and ensure that patients receive treatments that will provide the greatest benefit," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "This latest collaboration can significantly speed our understanding of targeted approaches for this complex and underserved form of lung cancer, while demonstrating how genomic testing can drive the evolution of clinical trial design. It may ultimately tell us more about how best to match patients to the right treatments."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- USDA Microbiologist Warns Bacteria In Vaping Products May Be A Health Concern
- Kudos To "The Independent" Newspaper For Debunking Nibiru "Blood Moon" Hoax
- Free Market Validation: Men With Hair Transplants Are Seen As Younger, More Attractive
- Sudden Death In Hypertrophic Cardiomyopathy - The Exercise Didn't Do It
- Your Microbiome Did Not Cause Your Weight Problem
- A Great Blitz Game
- Control Cancer By Making The Tumor Cell Environment Hostile
- "You have a point. Let me find out how this got misconstrued...."
- "So what's your excuse? Try googling the actual study abstract, it's called 'Bacterial Populations..."
- "It seems to me to be the ultimate in irony to commit suicide now, because of the belief that in..."
- "The image problem with the vaping community is that proponents smack of zealotry. This is a great..."
- "Sigh. Not only is it common sense to wash out your drinking cup/a vaping device tip, my own dental..."
- How Herpes Drugs Work
- The Infrared Sauna: Hollywood's Hot, Pricey 'Magic' Box
- E-Cigarette Flavors, Biotech Courts And More Media Links
- <a href="/news/2016/08/29/pediatricians-crack-down-anti-vaxx-parents-policy-report-says-9930">Pediatricians To Crack Down On Anti-Vaxx Parents, Policy Report Says <i class="fa fa-angle-double-right"></i></a>
- <a href="/news/2016/08/29/high-drug-costs-blame-playa-or-play-9873">High Drug Costs - Blame The Playa Or The Play? <i class="fa fa-angle-double-right"></i></a>
- <a href="/node/9873">High Drug Costs - Blame The Playa Or The Play? <i class="fa fa-angle-double-right"></i></a>
- Researchers identify characteristic chemical signature for chronic fatigue syndrome
- Isotope study determines fish were more prominent in early Alaskans' diets
- Tiny changes in Parkinson's protein can have 'dramatic' impact on processes behind onset
- Climate change has less impact on drought than previously expected
- Five-year study reveals patients operated on at night twice as likely to die as patients who have daytime operations